April 23, 2024

Accelerated Diagnoses for Rare Genetic Diseases Offered by Single Genomic Test

A breakthrough in genetic testing could revolutionize the diagnosis of rare developmental disorders in children, potentially replacing the current two-step process. The innovative approach, developed by researchers from the Wellcome Sanger Institute in collaboration with the University of Exeter and the University of Cambridge, aims to provide faster and more accurate diagnoses for families while also saving crucial resources for the NHS.

In their recent study published in Genetics in Medicine, the research team analyzed genetic data from nearly 10,000 families participating in the Deciphering Developmental Disorders study. The findings demonstrate that utilizing exome sequencing, which focuses on protein-coding DNA, is as effective if not superior to conventional microarrays in identifying disease-causing structural genetic variations.

The adoption of this single-genomic test offers a promising solution for the timely diagnosis of rare genetic diseases, potentially leading to significant cost savings for the healthcare system. However, researchers emphasize the importance of additional training for specialists to effectively generate and interpret the data obtained through this approach.

Large-scale genetic variations, such as copy number variations (CNVs), can be challenging to detect and understand using traditional sequencing methods. While these variations are often harmless, they can also underlie various neurodevelopmental disorders. The current diagnostic process for children suspected of having such genetic diseases involves multiple tests, starting with a microarray analysis before progressing to more comprehensive genome-wide sequencing.

The team’s single-assay approach, developed using data from the Deciphering Developmental Disorders study, combines machine learning algorithms to analyze exome sequencing data. By comparing this approach to standard clinical methods, the researchers demonstrated its ability to detect 305 pathogenic mutations, including 91 previously undetectable with microarrays.

Caroline Wright, a professor of genomic medicine at the University of Exeter and author of the study, highlights the significance of using exome sequencing to identify both large-scale and small genetic variations in a single test. The simplified and cost-effective nature of this approach could potentially streamline the diagnostic process for families seeking answers for genetic disorders.

Professor Helen Firth, lead clinician at the University of Cambridge and co-author of the study, envisions a future where families may only need one genetic test for accurate diagnoses, eliminating the current complex and time-consuming testing procedures for children.

Professor Matthew Hurles, director of the Wellcome Sanger Institute and senior author of the study, emphasizes the importance of computational methods in accurately detecting large-scale genetic variations. The research findings support the widespread implementation of this single-genomic test in clinical practice, emphasizing the need for proper bioinformatics training to support its integration into healthcare systems like the NHS.

In conclusion, the development of a single genomic test holds promise for transforming the diagnostic process for rare genetic diseases, offering accelerated and more cost-effective solutions for families and healthcare providers.

Note:
1. Source: Coherent Market Insights, Public sources, Desk research
2. We have leveraged AI tools to mine information and compile it